+

PE20060302A1 - Derivados de benzazepina como antagonistas del receptor h3 - Google Patents

Derivados de benzazepina como antagonistas del receptor h3

Info

Publication number
PE20060302A1
PE20060302A1 PE2005000691A PE2005000691A PE20060302A1 PE 20060302 A1 PE20060302 A1 PE 20060302A1 PE 2005000691 A PE2005000691 A PE 2005000691A PE 2005000691 A PE2005000691 A PE 2005000691A PE 20060302 A1 PE20060302 A1 PE 20060302A1
Authority
PE
Peru
Prior art keywords
cyclopentil
tetrahydro
benzazepin
pyrrolidinone
receptor antagonists
Prior art date
Application number
PE2005000691A
Other languages
English (en)
Inventor
Mark James Bamford
Paula Louise Pickering
David Matthew Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413770A external-priority patent/GB0413770D0/en
Priority claimed from GB0413763A external-priority patent/GB0413763D0/en
Priority claimed from GB0413764A external-priority patent/GB0413764D0/en
Priority claimed from GB0413757A external-priority patent/GB0413757D0/en
Priority claimed from GB0413765A external-priority patent/GB0413765D0/en
Priority claimed from GB0413769A external-priority patent/GB0413769D0/en
Priority claimed from GB0413758A external-priority patent/GB0413758D0/en
Priority claimed from GB0413768A external-priority patent/GB0413768D0/en
Priority claimed from GB0413766A external-priority patent/GB0413766D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20060302A1 publication Critical patent/PE20060302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS SELECCIONADOS DE: 1-{6-[(3-CICLOPENTIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-IL)OXI]-3-PIRIDINIL}-2-PIRROLIDINONA; 1-{5-[(3-CICLOPENTIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-IL)OXI]-2-PIRAZINIL}-2-PIRROLIDINONA; 3-{6-[(3-CICLOPENTIL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-IL)OXI]-3-PIRIDAZINIL}-1,3-OXAZOLIDIN-2-ONA; ENTRE OTROS. UN PROCEDIMIENTO DE PREPARACION CONSISTE EN: A) HACER REACCIONAR 7-HIDROXI-3-CICLOPENTIL-2,3,4,5-TETRAHIDRO-3-CICLOPENTIL-3-BENZAZEPINA CON 3-(PIRROLIDIN-2-ONA-PIRIDIN-6-IL-L1, DONDE LI ES HALOGENO, HIDROXILO OPCIONALMENTE ACTIVADO; B) HACER REACCIONAR 1-[6-(2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPIN-7-ILOXI)-PIRIDINIL]-2-PIRROLIDINONA CON CICLOPENTIL-L2, DONDE L2 ES HALOGENO Y LUEGO CON CICLOPENTANONA; C) REACCIONAR EL PRODUCTO RESULTANTE CON PIRROLIDINONA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR H3 DE HISTAMINA, UTILES EN EL TRATAMIENTO DE DE TRASTORNOS NEUROLOGICOS Y PSIQUIATRICOS
PE2005000691A 2004-06-18 2005-06-16 Derivados de benzazepina como antagonistas del receptor h3 PE20060302A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0413770A GB0413770D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413763A GB0413763D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413764A GB0413764D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413757A GB0413757D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413765A GB0413765D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413769A GB0413769D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413758A GB0413758D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413768A GB0413768D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413766A GB0413766D0 (en) 2004-06-18 2004-06-18 Novel compound

Publications (1)

Publication Number Publication Date
PE20060302A1 true PE20060302A1 (es) 2006-04-08

Family

ID=34971297

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000691A PE20060302A1 (es) 2004-06-18 2005-06-16 Derivados de benzazepina como antagonistas del receptor h3

Country Status (7)

Country Link
US (1) US20070232590A1 (es)
EP (1) EP1756094A1 (es)
JP (1) JP2008502644A (es)
AR (1) AR051919A1 (es)
PE (1) PE20060302A1 (es)
TW (1) TW200611701A (es)
WO (1) WO2005123723A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1572215T3 (da) * 2002-12-20 2010-01-11 Glaxo Group Ltd Benzo[D]azepin-derivater til behandling af neurologiske lidelser
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
AU2008231020B2 (en) 2007-03-23 2013-09-05 Wisconsin Alumni Research Foundation Somatic cell reprogramming
EP2326625A1 (en) * 2008-07-18 2011-06-01 Takeda Pharmaceutical Company Limited Benzazepine derivatives and their use as hstamine h3 antagonists
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011083315A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Compounds and their use
WO2011083314A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2011083316A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210749A (en) * 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
WO1993023431A1 (en) * 1992-05-14 1993-11-25 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2408913A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
JP2005522452A (ja) * 2002-02-13 2005-07-28 グラクソ　グループ　リミテッド Ｃｎｓ疾患の治療のための、５−ｈｔ６受容体アフィニティーを有する７−アリールスルホンアミド−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ’ジアゼピン誘導体
CA2475783A1 (en) * 2002-02-13 2003-08-21 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
AU2003218660A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
DK1572215T3 (da) * 2002-12-20 2010-01-11 Glaxo Group Ltd Benzo[D]azepin-derivater til behandling af neurologiske lidelser
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
TW200611701A (en) 2006-04-16
JP2008502644A (ja) 2008-01-31
AR051919A1 (es) 2007-02-21
US20070232590A1 (en) 2007-10-04
WO2005123723A1 (en) 2005-12-29
EP1756094A1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
PE20060302A1 (es) Derivados de benzazepina como antagonistas del receptor h3
PE20071116A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
US9850228B2 (en) Pyrazolyl quinoxaline kinase inhibitors
JP4179879B2 (ja) Ｎ−置換非アリール系複素環ｎｍｄａ／ｎｒ２ｂ拮抗薬
US7485641B2 (en) Substituted 3-amino-pyrrolidino-4-lactams
US11571420B2 (en) Pyrazine compounds and uses thereof
CA2900748C (en) Novel pyrimidine and pyridine compounds and their usage
US8623857B2 (en) N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
CA2959194A1 (en) 4-substituted-2-(n-(5-substituted allyl amide)phenyl)amino)pyrimidine compound, its use as an egfr inhibitor, and preparation and application thereof
BRPI0709660A2 (pt) derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
NZ706236A (en) Antiviral compounds
PE20070750A1 (es) COMPUESTOS DERIVADOS DE 1-AZA-BICICLONONANO COMO LIGANDOS COLINERGICOS DEL RECEPTOR DE ACETILCOLINA NICOTINICA (nAChR)
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
KR20170118166A (ko) 1-헤트(아릴)설폰일-(피롤리딘 또는 피페리딘)-2-카복스아마이드 유도체 및 trpa1 길항제로서의 이의 용도
US20180148429A1 (en) Substituted quinoxaline derivatives
PE20070407A1 (es) Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina
JP2008056659A5 (es)
AU2006285641A1 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
MX2014014110A (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
CZ20033053A3 (en) Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
KR20140071513A (ko) Gpr-119의 조절제로서의 신규한 화합물
HUE025031T2 (en) Ethinyl derivatives as positive allosteric modulators of MGLUR5
CA2851082A1 (en) 1,3-substituted azetidine pde10 inhibitors
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
ATE400553T1 (de) 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载